How to Determine Whether or Not a SCT is Successful image

How to Determine Whether or Not a SCT is Successful

Mar 03, 2022
02:00PM - 03:00PM EST
Online Event
Overview

Many patients understandably experience intense frustration when their stem cell transplant doesn't put them into full remission. Others feel real disappointment when after such an intense procedure, their labs still don't reflect MRD negativity. Dr. Guido Tricot joins the Stem Cell Transplant Chapter to share his thoughts on what constitutes a stem cell transplant procedure as "successful" or "unsuccessful". Come with your questions for Dr. Tricot and learn together with our Chapter.

Agenda
02:00 PM
Introduction
Audrey Burton-Bethke
Audrey introduces the agenda of the event and featured speaker Dr. Guido Tricot.
02:05 PM
Presentation
Dr. Guido Tricot
Dr. Tricot shares his thoughts on what constitutes a stem cell transplant procedure as "successful" or "unsuccessful".
02:35 PM
Questions and Answers
Audience
Type your questions in the chat and we will answer them! 
Speakers & Moderators
Healthtree contact Audrey Burton-Bethke

Audrey Burton-Bethke

Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Healthtree contact Dr. Guido Tricot

Dr. Guido Tricot

Dr. Tricot's most recent clinical studies focus on not only attacking myeloma cells but also the microenvironment that supports the survival and growth of myeloma cells. His work aims at finding treatments that are non-cross-resistant with current chemotherapy and therefore can eradicate the drug-resistant myeloma cells. His work on detailed genetics of myeloma cells should allow individualized therapies to ensure the greatest efficacy, while minimizing toxicity. Over the last 15 years, the median survival for patients newly diagnosed with myeloma has, in large part due to this work, increased from 2.5 to more than 10 years. The complete remission rate has increased from 5% to 80% and one third of all patients are still in complete remission at 10 years. He received his medical degree from Catholic University of Leuven and has been in practice for more than 20 years.